APVO
What one share of Aptevo Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and six preclinical candidates currently in development.
Aptevo Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$31.48 |
|---|---|
| Cash and investments | $6.90 |
| Book value | $4.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.49 | −$5.55 | $0.12 | −$1.95 | — | $2.49 |
| 2017 | $0.69 | $0.33 | $0.07 | −$2.01 | — | $3.80 |
| 2018 | $1.03 | −$2.39 | $0.04 | −$2.33 | — | $1.33 |
| 2019 | $11.12 | −$13.87 | $0.05 | −$14.58 | — | $3.66 |
| 2020 | $1.27 | −$5.23 | $0.03 | −$8.67 | — | $3.76 |
| 2021 | $2.62 | −$6.07 | $0.15 | −$4.78 | — | $0.25 |
| 2022 | $0.61 | $1.57 | $0.01 | −$4.13 | — | $2.78 |
| 2025 | — | −$87.27 | — | −$81.11 | — | $17.42 |